Advertisement

ResearchIn-Press PreviewInfectious diseaseVirology Open Access | 10.1172/JCI194586

Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine

Chandru Subramani,1 Michelle N. Meyer,1 Matthew A. Hyde,2 Margaret E. Comeaux,2 Haiping Hao,3 James E. Crowe Jr.,4 Vsevolod L. Popov,1 Harshwardhan Thaker,1 Sunny Himansu,5 Andrea Carfi,5 and Alexander Bukreyev1

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Subramani, C. in: PubMed | Google Scholar

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Meyer, M. in: PubMed | Google Scholar |

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Hyde, M. in: PubMed | Google Scholar

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Comeaux, M. in: PubMed | Google Scholar

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Hao, H. in: PubMed | Google Scholar

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Crowe Jr., J. in: PubMed | Google Scholar |

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Popov, V. in: PubMed | Google Scholar

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Thaker, H. in: PubMed | Google Scholar

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Himansu, S. in: PubMed | Google Scholar

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Carfi, A. in: PubMed | Google Scholar

1Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, United States of America

2Animal Resources Center, University of Texas Medical Branch at Galveston, Galveston, United States of America

3Department of Biochemistry & Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, United States of America

4Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, United States of America

5Moderna Inc., Cambridge, United States of America

Find articles by Bukreyev, A. in: PubMed | Google Scholar |

Published July 3, 2025 - More info

J Clin Invest. https://doi.org/10.1172/JCI194586.
Copyright © 2025, Subramani et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published July 3, 2025 - Version history
View PDF
Abstract

Although virus-like particle (VLPs) vaccines were shown to be effective against several viruses, their advantage over vaccines which include envelope protein only is not completely clear, particularly for mRNA-encoded VLPs. We conducted a side-by-side comparison of the immunogenicity and protective efficacy of mRNA vaccines encoding for the Marburg virus (MARV) full-length GP delivered alone or as a VLP. Electron microscopy confirmed VLP formation when MARV GP and matrix protein VP40 co-expressed. We vaccinated guinea pigs with a two-component mRNA vaccine encoding for GP and VP40 (VLP) or GP alone. At the highest dose, both vaccines protected fully, although the VLP vaccine elicited a slightly lower humoral response than the GP-only group. However, at low doses, GP-only mRNA conferred 100% protection, whereas the VLP exhibited only partial protection. In mice, VLP mRNA induced a moderate preference for GP-specific CD8+ T cells responses, whereas the GP-only mRNA somewhat favored CD4+ T cell responses. Guinea pig whole blood RNA-seq revealed that the VLP vaccine down-regulated genes associated with various biological and metabolic processes, including the NF-κB signaling pathway, whereas the GP-only vaccine upregulated interferon signaling. Overall, the VLP mRNA vaccine was less immunogenic and protective, whereas the GP-only mRNA vaccine conferred robust protection by as little as one µg dose in guinea pigs.

Graphical Abstract
graphical abstract
Supplemental material

View Unedited blot and gel images

View

View Supplemental Data 1

View Supplemental Data 2

View

Version history
  • Version 1 (July 3, 2025): In-Press Preview
Advertisement
Advertisement